Isocitrate dehydrogenase 2 (IDH2) is mutated in roughly 10% of acute myeloid leukemia (AML) cases. However, the clonal evolution of IDH2 mutations through the course of AML has not been clearly ...
Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...
A genetic alteration that is already routinely analyzed in patients with acute myeloid leukemia can be used to identify patients who respond to a new targeted therapy, according to a study published ...
The following article features coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to read more of MPR‘s conference coverage. Among patients with high-risk, ...
Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a new study. Researchers revealed new insights into how acute myeloid leukemia (AML) ...
The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and ...
Treatment with vorasidenib significantly improved progression free survival compared with placebo. The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib) for the treatment of adult ...
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has ...
A genetic alteration that is already routinely analysed in patients with acute myeloid leukaemia can be used to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results